Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration

A. Calcagno, C. Pinnetti, A. De Nicolò, E. Scarvaglieri, M. Gisslen, M. Tempestilli, A. D'Avolio, V. Fedele, G. Di Perri, A. Antinori, S. Bonora

Research output: Contribution to journalArticlepeer-review


Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV-positive patients taking abacavir once daily and twice daily, respectively. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng ml−1, P = 0.038 and 123 vs. 49 ng ml−1, P = 0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, P = 0.500). CSF abacavir concentrations were adequate in patients receiving once-daily treatment.

Original languageEnglish
Pages (from-to)1380-1383
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Issue number6
Publication statusPublished - Jun 1 2018


  • abacavir
  • age
  • central nervous system
  • cerebrospinal fluid
  • pharmacokinetics
  • protease inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration'. Together they form a unique fingerprint.

Cite this